Novartis and Johnson & Johnson to deprive Europeans of their right to Health

Novartis-Logo (1)

It was the last day of January that the European Commission decided to send a formal complaint against two pharmaceutical giants, Johnson and Johnson and Novartis, over an illegal secret deal that made European cancer patients suffer while it brought huge profits to the American and Swiss multinational accordingly.

After the meticulous research of DG Competition, that as usually, took around 10 years to bear fruit, it has been uncovered that the two of the three biggest Pharmaceutical companies of the world according to Forbes, were having a small party in Netherlands between 2005 and 2006 at the expense of the Dutch cancer patient. According to DG Comp, what was happening back then is that the Dutch branch of Johnson & Johnson in the Netherlands, Janssen-Cilag, had in its payroll for one year and a half a competitive pharmaceutical company specialized in generics called Sandoz. The latter is a proper known unit of the Swiss company Novartis. So, basically, Johnson and Johnson were paying to Novartis a huge amount of money for 17 months. Isn’t that weird? Competitor companies are supposed to have endless board meetings on how to steal money from each other and not sharing bribes. Was 2005 the year that the management of the two powerful companies lost their minds due to burnout?

The Pay for Delay Deal

Well, think again! These people knew very well what they were doing. We are talking here about the anticompetitive bad practice of Pharmaceuticals called “Pay for Delay” where one brand name is bribing the generic drug competitor in order to delay the release of the cheaper generic drug in the market. In our case the generic drug that was deliberately and illegally delayed to launch in the Dutch market is Fentanyl and it is a drug that is mainly used by cancer patients to relieve pain. In a nutshell, these two companies deprived the Dutch cancer patients from the right to be able to buy a much cheaper drug, so that they can save millions of Euros by preventing a market share loss that a cheaper substitute product in the market would bring.

On the antitrust statement of DG Competition on the 31st of January, Mr. Almunia, the EU Competition Commissioner, said: “If our preliminary conclusions are confirmed, the Dutch subsidiaries of Johnson & Johnson and Novartis entered into a so-called “co-promotion” agreement to avoid competing against each other, depriving users of fentanyl in the Netherlands from access to a cheaper pain killer,”… “The commission is determined to fight undue delays in the market entry of generic medicines so that European citizens have access to affordable health care”. The Basque EU Commissioner says it here very well, but he certainly cannot say anything to the Dutch patients that were not given the alternative of cheap Fentanyl for 17 monhts! Can he?

DG Comp is doing Fundraising

Unfortunately, it seems that this antitrust statement can serve only in two things: a) make impression and b) make the Commission richer. If the Commission wins this battle with the pharmaceutical dinosaurs, which we all hope it will, the only benefit will be a few billion Euros for DG Comp. And of course we live in crisis and Mr. Almunia needs to play the role of the Fundraiser but in the end of the day this will not solve the Pay for Delay syndrome that is expanding like a plague in Europe and is menacing significantly public health. I mean, what is 7 billion euros for Johnson and Johnson to pay as fine compared to the millions or billions that the company has probably saved by exercising this anticompetitive covert technique? And of course, we are talking here about one case that goes back 10 years ago and was uncovered now. Who knows how many other similar incidents we had or we have at this moment in Europe happening at the expense of the European citizen, which will never see the light of publicity? Hence, the culminant question here is: What next? How can the European citizen be sure that this kind of corporate bribing will not be repeated in the future?

The European Parliament had an idea

Only a week after the antitrust statement, a new draft law was voted on the 6th of February in the European Parliament that seems relevant to the topic of this story. The basic concept behind that is that European patients should be able to buy cheaper generic medicines. This is an excellent concept. The European Sting and all Europeans welcome this spirit from the European law makers without a doubt. However, the European Parliament only voted in favour of some new deadlines and transparency standards on pricing and reimbursement of generic medicines. As usually, all this will be addressed to the 27 member states.

Of course, this is something that Europe needed to have anyway, because the rules that are now in action and describe these procedures are almost 25 years old (1989). It is true that the procedures were poorly defined and slow while, as Mrs. Antoniya Parvanova, rapporteur from the Alliance of Liberals and Democrats for Europe (ALDE), said, sometimes it took a country up to 700 days to make decisions on pricing and reimbursement of medicines. However, why was this matter brought up in the European Parliament now and not before? Is it to take the next step after Mr. Almunia’s antitrust statement?

I am afraid not. The reasons are twofold:

a)      This vote apparently is not going to stop Pharmaceuticals to pay for delay

b)      The draft law was voted on the 6th of February, when on the 4th was the World Cancer Day. The period that the draft law was voted was a period with numerous events aiming at cancer awareness all around the world. Is it a coincidence that the flash addicted European Parliament voted for this in the beginning of February and not in March?

Overall the draft law is a good reform addressed to member states to improve the European health system as a whole but let’s be honest here. Big Pharmaceuticals will be still free out there to sign golden deals under the table with generic competitors, in order to delay the launch of their product so that they keep the prices and profits high for themselves. Who will touch these people? Or better who can touch these people? Is a few billion fine enough to make them stop?

I guess not. The only cure from this cancer is that the patient, the European citizen, is aware of what exactly is happening behind her back and I hope that with this story the Sting has contributed to that.

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Featured Stings

The Banking Union may lead to a Germanic Europe

Do the EU policies on agro-food smell?

Eurozone governed by an obscure body and gray procedures

China Unlimited – The chinese tourism in Lisbon

Eurobarometer: Not a single answer about what the Banking Union will cost to citizens

EFSF/ESM boss tells half truths about Troika’s doings

The International Federation of Medical Students’ Associations (IFMSA) on the arrest of Turkish Medical Association leaders

China is the first non-EU country to invest in Europe’s €315 billion Plan

“Be aware where you put your I Agree signature on and something else”; now Facebook by default opts you in an unseen private data bazar

Security Council urged to act with ‘one strong voice’ on raft of ills plaguing Middle East and North Africa

Disintegrating Tories will void May’s pledge for Brexit deal in seven weeks

A Sting Exclusive: “Climate change-the biggest global health threat of the 21st century, yet overlooked in climate negotiations?” IFMSA wonders from COP21 in Paris

What living abroad does to your self-awareness

Asylum: deal to update EU fingerprinting database

Eurozone plans return to growth

Why lay people don’t expect anything good from G20

Commission criticised member states on blocking financial transaction tax

Does the Erasmus program really contribute to the construction of a solid EU identity?

Italy’s rescue operation Mare Nostrum shuts down with no real replacement. EU’s Triton instead might put lives at risk

Strong multilateral institutions key to tackling world’s dramatic challenges, UN chief says In Moscow

ECB describes in detail how it exploits the poor

MWC 2016 LIVE: Mobile World Congress shows off planes, trams and automobiles

Depression is the no. 1 cause of ill health and disability worldwide

Junker for Commission President: What were the stakes in this affair

ILO and EIB join forces for more and better quality employment

How tomorrow’s buildings will make you – and the planet – healthier

From drought to floods in Somalia; displacement and hunger worsen, says UN

The Americans are preparing for the next financial crisis

2nd Global Consultation on Migrant Health 21-23 February 2017 in Sri Lanka

When is Berlin telling the truth about the EU banking union?

The consequences of Brexit seen by a European young entrepreneur

Commission imposes a fine of €561 million on Microsoft

UN Environment Assembly 2017: where the world convenes to #BeatPollution

Innovation and Entrepreneurship Changing the Face of Europe

Celebrate love, strengthen partnerships to end AIDS epidemic by 2030 says UN agency

Germany tries to save Europe from war between Ukraine and Russia

Millennials (and Gen X) – Here are the steps you should take to secure your financial future

Rehn ready to sacrifice part of the real economy

Easier Schengen Visas for non-EU holiday makers: A crucial issue for south Eurozone countries

WEF Davos 2016 LIVE: “No other problem has jeopardised the EU as much as the refugee question” Joachim Gauck, President of the Federal Republic of Germany, cries out from Davos

To all far-right partisans who exploit Charlie Hebdo atrocity: a peaceful reply given by a peaceful student

NATO summit, Brussels, 11-12/07/2018

The issue of mental health for modern young doctors

The European Youth Forum needs better signal for its “call” for Quality Internships

Medschool 4.0: how to succeed in the smart revolution of healthcare

CHINA: five letters that could mean…

Campaign kicks off with High-level Event on #FairInternships

MWC 2016 LIVE: Ford trumpets new in-vehicle system, “fundamentally rethinks” transportation

This Syrian national has been trapped at Kuala Lumpur airport for 3 months

The EU Commission fails to draw the right conclusions about corruption

What fighting malaria can teach us about linking purpose and business

The G7 fails to agree on growth but protects the big banks

‘Agile’, multilateral response vital to combat terrorism – UN chief Guterres

Why the West supports the yen’s devaluation and Japanese over-indebtedness

Macron crowned king of Europe in Washington D.C.; just a working meeting with Trump for Merkel

EU to fail 2050 Green targets due to lack of European citizens’ engagement

What Merkel and Macron are to tell Trump in Davos?

Catalonia secessionist leader takes Flemish ‘cover’; Spain risks more jingoist violence

A neo-liberal toll free Paradise for the super rich and tax hell for wage earners

Good Governance in developing modern quality infrastructure systems

More Stings?

Comments

  1. I believe this is one of the so much important information for me.
    And i’m satisfied studying your article. But wanna
    remark on few basic things, The site style is perfect, the articles is in point of fact excellent : D.
    Just right task, cheers

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s